PTT-3196 / Pathios Therap - LARVOL DELTA

Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for small molecule GPR65 inhibitor in human PDX cancer model (PRNewswire) - "In the research presented, Pathios evaluated the impact of PTT-3196, an orally bioavailable, potent and selective GPR65 inhibitor, on expression of key immune-related genes and tumor growth in a highly glycolytic RCC PDX model implanted in NCG mice that had been reconstituted with human immune cells...A dose-dependent increase in a host of genes known to be predictive of a successful response to T cell checkpoint inhibitors in the clinic including CD3D, CD3E, IL2RG, CCL5 and CXCl10; A suppression of pro-tumorigenic genes including TGFB, IL10 and ADORA2A"

Preclinical • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma

[VIRTUAL] GPR65 is a critical mediator of low pH induced immunosuppressive signalling in tumor associated macrophages: Human target validation of GPR65 as a novel innate immune checkpoint and discovery of potent, selective GPR65 antagonists (AACR 2021) - "This work provides the basis for developing novel “macrophage conditioning” therapeutic agents that may have utility across a range of cancers, either as single agents or in combination with other approved immunoncology drugs. 1Nat Immunol 19:1319."

IO biomarker • Melanoma • Oncology • Solid Tumor • C18orf8